Estrogen accelerates the development of renal disease in female obese Zucker rats

被引:59
作者
Gades, MD
Stern, JS
van Goor, H
Nguyen, D
Johnson, PR
Kaysen, GA
机构
[1] Univ Calif Davis, Dept Nutr, Sch Med, Div Clin Nutr & Metab, Davis, CA 95616 USA
[2] Univ Calif Davis, Dept Internal Med, Sch Med, Div Nephrol, Davis, CA 95616 USA
[3] Univ Groningen, Dept Pathol, Groningen, Netherlands
[4] Dept Vet Affairs, No Calif Hlth Care Syst, Pleasant Hill, CA USA
关键词
albuminuria; diabetes; estrogen; nephrotic syndrome; obese rat;
D O I
10.1046/j.1523-1755.1998.00746.x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Renal failure is the primary cause of death in obese Zucker rats (OZR). We previously found that renal injury occurred earlier and with greater severity in female OZR; also, prevention of hyperphagia decreased renal damage in females more than males. To examine the relationship between estrogen (E), hyperphagia, hyperlipidemia, and renal injury in female OZR, we studied four groups from 5 to 10 or 21 weeks of age: Sham-operated (Sham), ovariectomized (Ovx), Ovx with estrogen treatment (Ovx+E), and, since Ovx increases food intake, Ovx pair-fed to sham (Ovx-PF). By only six weeks of age, albumin excretion (UAE) increased significantly in Ovx+E (9.9 +/- 4.1 mg/day). Ovx+E also ate least and gained the least weight, bur had the highest plasma lipid levels. In contrast, UAE in Ovx did not increase by 10 weeks of age, despite a significantly greater food consumption. The hyperlipidemia of Ovx+E was due primarily to triglycerides. Both plasma triglycerides and renal injury, judged from either histology or UAE, were greatest in the Ovx+E group. Fasting plasma glucose was lower and insulin was higher in Ovx+E compared to Ovx rats at 15 weeks of age. Estrogen may promote renal injury in female OZR by increasing the plasma concentration of triglyceride-rich lipoproteins.
引用
收藏
页码:130 / 135
页数:6
相关论文
共 39 条
[21]  
Lee H C, 1993, Obes Res, V1, P371
[22]  
LYNN C, 1997, ENDOCRINOLOGY, V138, P143
[23]  
MCDONNELL MP, 1985, J LAB CLIN MED, V106, P605
[24]   MASSIVE HYPERLIPEMIA DURING ESTROGEN THERAPY [J].
MOLITCH, ME ;
OILL, P ;
ODELL, WD .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1974, 227 (05) :522-525
[25]   BIOCHEMICAL, CLINICAL, AND GENETIC FEATURES OF TYPE-III HYPERLIPOPROTEINEMIA [J].
MORGANROTH, J ;
LEVY, RI ;
FREDRICKSON, DS .
ANNALS OF INTERNAL MEDICINE, 1975, 82 (02) :158-174
[26]   ASSOCIATION OF HORMONE-REPLACEMENT THERAPY WITH VARIOUS CARDIOVASCULAR RISK-FACTORS IN POSTMENOPAUSAL WOMEN [J].
NABULSI, AA ;
FOLSOM, AR ;
WHITE, A ;
PATSCH, W ;
HEISS, G ;
WU, KK ;
SZKLO, M .
NEW ENGLAND JOURNAL OF MEDICINE, 1993, 328 (15) :1069-1075
[27]  
OSCHRY Y, 1982, J LIPID RES, V23, P1099
[28]   HYPOPHYSECTOMY AND REGULATION OF BODY-WEIGHT IN GENETICALLY OBESE ZUCKER RAT [J].
POWLEY, TL ;
MORTON, SA .
AMERICAN JOURNAL OF PHYSIOLOGY, 1976, 230 (04) :982-987
[29]   MESANGIAL IMMUNE INJURY, HYPERTENSION, AND PROGRESSIVE GLOMERULAR DAMAGE IN DAHL RATS [J].
RAIJ, L ;
AZAR, S ;
KEANE, W .
KIDNEY INTERNATIONAL, 1984, 26 (02) :137-143
[30]   Postprandial lipoprotein metabolism in normotriglyceridemic non-insulin-dependent diabetic patients: Influence of apolipoprotein E polymorphism [J].
Reznik, Y ;
Pousse, P ;
Herrou, M ;
Morello, R ;
Mahoudeau, J ;
Drosdowsky, MA ;
Fradin, S .
METABOLISM-CLINICAL AND EXPERIMENTAL, 1996, 45 (01) :63-71